The purpose of this study was to determine whether mitral valve plasty (MVP) under cardiopulmonary bypass would better improve the prognosis of dogs with mitral valve disease (MVD) than treatment with internal medicine.
This study was a retrospective review of medical records to identify dogs with MVD that underwent surgical repair or medical management of MVD. In the internal medicine group, 105 dogs were studied. The dogs in this group were treated chronically with ACE inhibitors, pimobendan, diuresis (thiazide, spironoractone, furosemide, and torsemide), vasodilators (amlodipine, nitroglycerin, isosorbide), and sildenafil. In the surgery group, 92 dogs with mitral valve regurgitation, with a mean age of 10 (8.3-11) years and mean body weight of 3.9 (1.9-20.9) kg, underwent mitral valve plasty with cardiopulmonary bypass (CPB) between July 2016 and October 2017.
In the internal medicine group, median survival times were 649 days (stage B2), 220 days (stage C), and 52 days (stage D). In all cases, the dogs died due to heart failure. In the surgical group, the discharge ratios were 100% (19/19), 93.1% (54/58), and 80% (12/15) for stages B2, C, and D, respectively. Median survival times were undefined because almost patients survived. Survival ratios were 94.7% (18/19), 90.0% (52/58), and 73.3% (11/15) for stages B2, C, and D, respectively. Mean survival times were 825 days (stage B2), 771.3 days (stage C), and 733.6 days (stage D). One dog died from renal failure in stage B2 at 605 days. The causes of death in stage C were technical problems (n=2), protamine shock (n=1), residual pulmonary damage (n=1), and unknown (n=2). The causes of death in stage D were heart failure (n=2), residual pulmonary damage (n=1), and renal failure (n=1).
These results suggest that MVP is more effective than medical therapy for the treatment of MVD, and earlier surgery is recommended.
Friday, June 15
4:15 PM – 4:30 PM
The asset you are trying to access is locked. Please enter your access key to unlock.